Thuja Capital

What Thuja Capital does

Thuja Capital Management BV is a privately-held, Netherlands-based venture capital firm founded in 2005 by Harrold van Barlingen, headquartered in Leiden. The firm specializes in early-stage life sciences investments across the Netherlands, Belgium, and Germany, backing companies developing novel therapeutics, medical devices (including digital health), and nutraceuticals, frequently at the academic spin-off or preclinical proof-of-concept stage. Thuja operates multiple specialized vehicles: TCHF I, II, III, and IV (Thuja Capital Healthcare Funds), and Magnolia MedTech Fund I, with TCHF III closing at EUR 76M (USD 86M) in December 2021 and a portfolio spanning more than 30 companies. Its investor base (limited partners) includes the European Investment Fund, ASR, Dutch and Walloon regional investment agencies, and a consortium of Dutch and Belgian university knowledge institutions such as Sanquin, Utrecht University, UMC Utrecht, Radboud UMC, KU Leuven, and Delft Enterprises.

The firm monetizes through standard venture capital economics: recurring management fees on committed capital from institutional LPs, supplemented by performance-based carried interest on portfolio exits. It does not sell software, products, or services; rather, it deploys capital into portfolio companies, takes board or observer roles, and provides hands-on support leveraging sector expertise and an academic-clinical-industry network. Notable value-creation milestones include Argenx (USD 700M raise and FDA approval of Vyvgart), MILabs (acquired by Rigaku), and EsoBiotec (acquired by AstraZeneca).

As of 2026, Thuja operates with approximately ten professionals under Managing Partner Michel Briejer and partners including Evan Castiglia (ex-Philips Ventures), following the January 2025 passing of founder Harrold van Barlingen. The firm is a member of Dutch venture associations and is supported by EIF, which signals institutional credibility. Its go-to-market is relationship-driven and selective, anchored by annual events (CEO Day, Portfolio Day), a proprietary impact/ESG reporting framework, and a website-plus-LinkedIn presence, rather than broad marketing campaigns.

Name

Thuja Capital

Legal name

Thuja Capital Management BV

Website

https://thujacapital.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Venture Capital / Healthcare Investment Management

NAICS

Other Investment Pools and Funds (5259), Portfolio Management and Investment Advice (523940)

akta.pro primary industry

Venture Capital Fund-of-Funds / Multi-Manager Platforms (FSANAAAJ)

Keywords

• Venture capital management
• Life sciences investing
• Healthcare venture capital
• Early-stage investment
• Biotech and medtech funding

Headquarters

HQ city

Utrecht

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Management fees: VC fund management fees charged on committed capital from institutional investors including EIF, ASR, Dutch and Walloon regional investment agencies, and universities.
2. Carried interest: Performance-based carried interest from successful portfolio company exits, with Argenx being cited as the biggest success from Fund I.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Thuja Capital is an early-stage venture capital firm that manages healthcare-focused investment funds (TCHF I-IV and Magnolia MedTech Fund I) providing equity capital, active management support, board participation, and network access to life sciences companies developing novel therapeutics, medical devices, digital health products, and nutraceuticals in the Netherlands, Belgium, and Germany. Capital is sourced from institutional limited partners including the European Investment Fund, ASR, regional investment agencies, and universities.

Product overview

Thuja Capital is a venture capital firm that manages multiple investment funds (TCHF I, TCHF II, TCHF III, TCHF IV, and Magnolia MedTech Fund I) dedicated to investing in innovative life science companies in Europe. The firm focuses on early-stage investments in biotech and medtech companies, with a portfolio spanning therapeutics, medical devices, and digital health across the Netherlands, Belgium, and Germany.

Differentiator

Problem solved

Functional benefit

Brands

• Thuja Capital Healthcare Fund I (TCHF I): First venture capital fund focused on life sciences investments
• Thuja Capital Healthcare Fund II (TCHF II)
• Thuja Capital Healthcare Fund III (TCHF III)
• Thuja Capital Healthcare Fund IV (TCHF IV)
• Magnolia MedTech Fund I

Products and services

• Thuja Capital Healthcare Fund I (TCHF I) Thuja's first venture capital fund focused on early-stage life sciences investments; made investments in 10 companies including argenx, Thuja's biggest success.
• Thuja Capital Healthcare Fund II (TCHF II) Second venture capital fund by Thuja Capital investing in early-stage life sciences companies.
• Thuja Capital Healthcare Fund III (TCHF III) Third fund focused on early-stage companies developing novel therapeutics, medical devices (including digital health), or nutraceuticals in the Netherlands, Belgium, or Germany, targeting 10-12 portfolio investments. Final close at EUR 76M (USD 86m) in December 2021.
• Thuja Capital Healthcare Fund IV (TCHF IV) Fourth venture capital fund by Thuja Capital for early-stage life sciences investments, referenced in SFDR disclosures.
• Magnolia MedTech Fund I MedTech-focused investment fund investing in young medical technology companies addressing unmet medical needs.

Quantifiable outcome

• Argenx achieved $700M raise and FDA approval of Vyvgart
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• SanquinnovatecoreStrategic or Co-development Partner · 15 June 20215-year collaboration agreement between Sanquinnovate (Sanquin's technology valorization and business development arm) and Thuja Capital. Jointly evaluate projects and business plans regarding novel therapeutics and diagnostics. The aim is to progress excellent scientific projects into start-up companies. Alveron Pharma was co-founded in 2019 through prior collaboration between the parties.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Forbion: Forbion is one of Europe's largest dedicated life sciences venture capital firms, investing across stages in therapeutics and medtech from offices in the Netherlands and Germany. It is a direct peer to Thuja given overlapping focus on European early-stage biotech and shared Dutch institutional roots.
• EQT Life Sciences (formerly LSP): EQT Life Sciences is a pan-European healthcare investor operating from the Netherlands with multi-stage life sciences funds. It directly competes with Thuja for Dutch and Belgian biotech and medtech deals and overlaps on LP base through EIF and other institutional investors.
• BioGeneration Ventures (BGV): BGV is a Dutch venture capital firm focused on early-stage life sciences companies in the Netherlands, Belgium, and Germany. It directly competes with Thuja Capital in seed and Series A biotech investing across the same Benelux/DACH geography.
• Gilde Healthcare: Gilde Healthcare is a specialized European healthcare investor managing both venture and growth funds focused on therapeutics, medtech, and digital health. It is a direct peer to Thuja with overlapping geographies, fund focus, and target stages.
• Andera Partners: Andera Partners is a Paris-based private equity firm with dedicated life sciences venture and growth activities. It is a direct peer to Thuja given its focus on European biotech and medtech investing and competition for high-quality academic spin-out deals across the continent.
• Sunstone Capital: Sunstone Capital is a Copenhagen-based venture firm with a dedicated Life Sciences fund investing in European early-stage biotech and medtech. It directly competes with Thuja for pan-European seed and Series A opportunities and shares comparable fund sizes.
• Inkef Capital: Inkef Capital is a Dutch venture capital firm with a dedicated life sciences strategy investing in early-stage European therapeutics and medical technology. It is a direct peer to Thuja with overlapping geography, stage focus, and LP base including Dutch institutional investors.
• Seventure Partners: Seventure Partners is a Paris-based VC/PE firm managing life sciences-focused funds across Europe. It is a direct peer to Thuja given its early-stage biotech focus, comparable fund sizes, and competition for European academic spin-out transactions.
• Bracco Ventures / Panakes Partners: Panakes Partners is an Italian venture capital firm investing in early-stage life sciences companies across Europe. It is a direct peer to Thuja in fund size, stage focus, and target geography (though primarily Italy-anchored).

Regional players

• Innovationsfonden (Novo Seeds): Novo Seeds is the early-stage venture arm of Novo Holdings, focused on Danish and Nordic life sciences companies. It is a regional peer to Thuja — comparable in stage focus and life sciences vertical, but anchored in the Nordics rather than Benelux/DACH.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/thuja-capital
• Xx.com/ThujaCapital

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments62 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Thuja Capital